文献速递甲状腺核医学核素与放射性配体治疗放射性药物与辐射防护

甲状腺癌放射性碘治疗中甲状腺摄取与全身有效半衰期的比较:停用甲状腺激素与rhTSH准备

Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH.
PubMed 文献 · J Nucl Med · 2018-10-12

该回顾性研究分析了366例分化型甲状腺癌辅助放射性碘治疗患者,比较停用甲状腺激素与rhTSH准备对甲状腺摄取和全身有效半衰期的影响。结果显示停用甲状腺激素组全身半衰期显著较长(19.3±7.7 h vs 16.4±4.6 h,P<0.01),但甲状腺摄取无显著差异(4.2%±1.8% vs 3.8%±1.6%,P=0.12)。甲减期超过4周及GFR低于60 mL/min/1.73 m2的患者辐射暴露更高。

要点

  • 停用甲状腺激素组全身有效半衰期显著长于rhTSH组(19.3±7.7 h vs 16.4±4.6 h,P<0.01)。
  • 两组甲状腺摄取无显著差异(4.2%±1.8% vs 3.8%±1.6%,P=0.12)。
  • 甲减期>4周及GFR<60 mL/min/1.73 m2者停用甲状腺激素组辐射暴露更高。

核心结论

  • 手术与辅助放射性碘治疗间隔缩短后,停用甲状腺激素组甲状腺摄取无显著变化,但全身半衰期延长。
  • 大多数患者辐射暴露无显著差异,但甲减期超过4周及GFR降低者停用甲状腺激素组辐射暴露更高。

研究设计与样本

  • 回顾性研究,纳入2010年起5年内于科隆大学医院接受辅助放射性碘治疗的分化型甲状腺癌患者366例。
  • 剂量率测量分析366例,亚组分析包括乳头状癌341例、滤泡状癌25例、性别、甲减时长及GFR正常与降低。

主要发现

  • 手术至放射性碘治疗中位间隔:停用甲状腺激素组18天 vs rhTSH组25天(P<0.01)。
  • 平均甲状腺摄取:停用甲状腺激素组300例为4.2%±1.8% vs rhTSH组66例为3.8%±1.6%(P=0.12)。
  • 全身半衰期:停用甲状腺激素组19.3±7.7 h vs rhTSH组16.4±4.6 h(P<0.01),停用甲状腺激素组显著较长。
  • 结果主要受最大亚组即女性乳头状甲状腺癌患者影响,该组rhTSH组全身半衰期显著较短。
  • 甲减时长及GFR低于60 mL/min/1.73 m2显著影响结果,停用甲状腺激素组全身半衰期增加。

临床怎么用

  • 对于甲减期超过4周或GFR低于60 mL/min/1.73 m2的患者,停用甲状腺激素准备可能导致更高辐射暴露。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adjuvant radioiodine therapy (RITh) for differentiated thyroid carcinoma is performed either with thyroid hormone withdrawal or with administration of recombinant human thyroid-stimulating hormone (rhTSH). Heterogeneous results have been obtained on the impact of the method of patient preparation on thyroid uptake and whole-body effective half-life. A higher radiation exposure using thyroid hormone withdrawal for several weeks compared with rhTSH was reported in prior studies. It was the aim to examine whether these findings are reproducible in a modern protocol with a short interval between surgery and RITh. Methods: A retrospective study was performed on patients admitted for adjuvant RITh for differentiated thyroid carcinoma at the University Hospital of Cologne over a 5-y period from 2010. Dose rate measurements were analyzed for 366 patients, and subgroup analyses were performed for papillary thyroid cancer (n = 341) and follicular thyroid cancer (n = 25) patients, sex, length of hypothyroidism, and normal versus decreased glomerular filtration rate (GFR). Results: The median interval between surgery and RITh was 18 d for thyroid hormone withdrawal and 25 d for rhTSH (P < 0.01). The mean thyroid uptake was 4.2% ± 1.8% for the 300 hypothyroid patients versus 3.8% ± 1.6% (P = 0.12) for the 66 rhTSH patients. Whole-body half-life in the hypothyroid group was significantly longer at 19.3 ± 7.7 h versus 16.4 ± 4.6 h in the rhTSH group (P < 0.01). Results were predominantly influenced by data from the largest subgroup, that is, female papillary thyroid cancer patients. Within this group, whole-body half-life was significantly shorter in the rhTSH treatment arm. Duration of hypothyroidism and a decrease in GFR less than 60 mL/min/1.73 m2 significantly influenced results, with an increased whole-body half-life occurring in the hypothyroid group. When patients returned for whole-body scintigraphy, thyroid, half-life, and whole-body half-life were significantly shorter in the rhTSH groups, resulting in a low thyroid and remaining-body dose. Conclusion: With a shortening of the time between surgery and adjuvant RITh, thyroid uptake is not significantly changed but whole-body half-life becomes longer in the hypothyroid group. Radiation exposure for most patients is not significantly different. However, patients with a hypothyroid phase of more than 4 wk, and in particular those with a decreased GFR, experience higher radiation exposure.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bacher R, Hohberg M, Dietlein M, et al. Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH. J Nucl Med. 2018. PMID: 30315143. doi:10.2967/jnumed.118.217638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。